标签归档：vandetanib

Vandetanib-d4(Synonyms: 凡德他尼 d4)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Vandetanib-d4 (Synonyms: 凡德他尼 d4)

Vandetanib-d4 (ZD6474-d4) 是 Vandetanib 的氘代物。Vandetanib (ZD6474) 是一种有效的，具有口服活性的 VEGFR2/KDR 酪氨酸激酶抑制剂 (IC50=40 nM)。Vandetanib 也抑制 VEGFR3/FLT4 (IC50=110 nM) 和 EGFR/HER1 (IC50=500 nM)。

Vandetanib-d4(Synonyms: 凡德他尼 d4)

Vandetanib-d4 Chemical Structure

CAS No. : 1215100-18-7

规格 是否有货
2.5 mg Check price and availability
1 mg Check price and availability
5 mg Check price and availability
10 mg Check price and availability

* Please select Quantity before adding items.

生物活性

Vandetanib-d4 (ZD6474-d4) is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

479.38

Formula

C22H20D4BrFN4O2
CAS 号

1215100-18-7
中文名称

凡德他尼 d4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Wedge SR, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002 Aug 15;62(16):4645-55.

    [3]. Hegedus C, et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol. 2012 Aug 1;84(3):260-7.

    [4]. Takeda H, et al. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res. 2013 Feb 15;319(4):417-23.

    [5]. Inoue K, et al. Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice. Clin Cancer Res. 2012 Jul 15;18(14):3924-33.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务